Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Chemotherapy. Fondazione IRCCS Istituto Neurologico, Milan, Italy

Survival: 20.8 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Italy
City/State/Province: Milan
Hospital: Fondazione IRCCS Istituto Neurologico
Journal: Link
Date: 6/2007

Patients: This phase II trial involved 54 patients with glioblastoma multiforme. The patients ranged in age from 26 to 68 years old, with a median age of 53.5 years. The majority (75.9%) of patients were men. They had all received temozolomide.

Treatment: The patients received the chemotherapy drugs procarbazine and fotemustine.
Fotemustine is cytotoxic (it kills cells) and procarbazine slows or stops the growth of tumor cells by damaging DNA and RNA.

Toxicity: One patient developed deep vein thrombosis and another developed pneumonia (both grade 3). Grade 3 liver toxicity occurred in two patients. Grade 2 nausea and vomiting occurred in five patients. Grade 4 neutropenia and thrombocytopenia were reported in four and two patients, respectively.

Results: The median overall survival of these patients was 20.8 months from the time of first diagnosis. The median survival from the time of starting this treatment regimen was 28.7 weeks.

Correspondence: Dr. Antonio Silvani

E-mail to a Friend Email Physician More Information